Full-Time

Associate Director

Data & Analytics

Posted on 9/23/2025

BridgeBio

BridgeBio

501-1,000 employees

Develops therapies for genetic diseases

Compensation Overview

$185.5k - $235k/yr

+ Annual Performance Bonus + Equity

San Francisco, CA, USA

Hybrid

Hybrid role requiring 2-3 days in SF office per week.

Category
Data & Analytics (2)
,
Requirements
  • Bachelor’s degree in Computer Science, Data Science, Information Systems, or related field (Master’s or PhD preferred)
  • 7+ years of progressive experience in data strategy, data architecture, analytics, or related fields, with at least 5 years in a leadership role
  • Industry experience in biotech, pharmaceutical, or healthcare is highly preferred, including familiarity with the unique challenges of regulated data (e.g. clinical data, patient data, commercial pharma data)
  • Proven expertise in designing and managing modern data architectures and platforms. Hands-on knowledge of cloud-based data technologies (e.g. AWS, Azure, Databricks, Snowflake ecosystems), data warehousing and data lake concepts, data integration/ETL tools, and big data processing frameworks
  • Experience with business intelligence and analytics tools (e.g. Tableau, Power BI, Spark, Python/R for analytics) and AI/ML frameworks
  • In-depth understanding of data governance principles and best practices (data quality, MDM, metadata management, data lifecycle)
  • Experience implementing data governance programs and working with data stewardship councils
  • Strong background in analytics – able to guide teams in advanced analytics and oversee the development of predictive models or AI-driven data products
  • Solid knowledge of data privacy and security regulations relevant to life sciences (such as HIPAA, GDPR, CCPA) and familiarity with compliance standards in pharma/biotech (GxP, 21 CFR Part 11 for data systems, etc.). Demonstrated ability to ensure compliance in all data initiatives
  • Strategic thinker who can translate business strategy into effective data solutions. Outstanding communication skills – capable of articulating a vision and complex data concepts in simple terms to influence stakeholders at all levels. Strong cross-functional collaboration abilities to work effectively with commercial, scientific, IT, and compliance teams
  • Highly analytical and resourceful, with superior problem-solving abilities. Proven project management skills with the ability to oversee multiple initiatives and deliver results in a fast-paced environment. A drive for innovation and continuous improvement, with a “roll-up-your-sleeves” attitude to tackle challenges
  • Genuine passion for leveraging data and emerging technologies, such as AI, to advance healthcare and patient outcomes. Alignment with a patient-focused, science-driven culture – you thrive in an environment that values integrity, innovation, urgency, and collaboration
Responsibilities
  • Develop and execute a comprehensive data management and analytics strategy that aligns with organizational goals
  • Establish and enforce data governance policies, standards, and best practices
  • Maintain strict compliance with healthcare laws and guidelines (e.g. FDA regulations, GxP, HIPAA) and global data privacy standards (GDPR, CCPA)
  • Define and implement a Master Data Management (MDM) roadmap for the enterprise in collaboration with various business teams
  • Define data quality standards and implement assurance processes
  • Facilitate data integration across systems and sources for a unified view of organizational data
  • Monitor data quality metrics and spearhead efforts to address data issues
  • Establish capabilities for Data catalog, Metadata Management, and Data Dictionary
  • Implement data security protocols and access controls to safeguard sensitive data
  • Conduct regular data audits and risk assessments to ensure compliance
  • Evaluate and implement modern data technologies, tools, and platforms (cloud services, databases, ETL/ELT tools, analytics and AI platforms) that best fit our needs
  • Manage relationships with external vendors and data providers, negotiating contracts and ensuring high-quality service for data management, integration, and analytics solutions
  • Lead business intelligence and analytics teams for reporting and advanced analytics
  • Develop and deliver relevant Key Performance Indicators (KPIs) and Dashboards for various business teams
  • Ensure data is readily available and accessible for deriving business insights
  • Oversee the design and maintenance of data architectures, including data warehouses, data lakes, and data pipelines
  • Collaborate with Infrastructure teams to ensure data infrastructure scalability, reliability, and performance
  • Evaluate and recommend data management technologies and tools
  • Demonstrate a strong understanding of cloud architecture, security best practices, and cost optimization strategies
  • Proven experience in managing cloud infrastructure, with a focus on Azure and AWS
  • Drive the implementation of a “single source of truth” for all critical data, integrating information across R&D, clinical, commercial, and medical functions
  • Leverage artificial intelligence and machine learning to enhance our data capabilities
  • Enable advanced analytics and business intelligence by implementing AI/ML solutions that automate data cleansing and governance workflows, detect data anomalies, and power predictive modeling for key business outcomes (e.g. forecasting, patient insights)
  • Partner with departments across the entire organization to understand their data needs and pain points. Prioritize and deliver data solutions that support various functions – from commercial analytics and medical insights to compliance reporting – fostering a culture of data-driven innovation across the company
Desired Qualifications
  • Master’s degree or PhD preferred
  • Experience with data sovereignty, cross-border data transfer considerations, or other international data governance complexities is preferred
  • Experience with regulated data in pharma or biotech environments beyond standard HIPAA and GDPR familiarity is a plus

BridgeBio Pharma develops medicines for genetic diseases through a decentralized subsidiary model, with each subsidiary focused on a specific disease while sharing central resources. It advances multiple drug programs at once by using genome sequencing, molecular biology, and patient data to identify targets and translate research into therapies. Therapies target the underlying genetic causes to create disease-modifying treatments, and BridgeBio monetizes via licensing, partnerships, and eventual commercialization of approved drugs. The company differentiates itself by its independent subsidiaries with centralized support, data-driven decision making, and a culture of radical transparency, all to accelerate discovery and bring therapies to patients faster.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Attruby sales hit $146M in Q4 2025 with 44.7% mortality reduction.
  • BBP-418 meets Phase 3 endpoints in LGMD2I/R9 FORTIFY trial May 2026.
  • Farallon Capital boosts stake to 9M shares signaling pipeline confidence.

What critics are saying

  • Pfizer's Vyndamax erodes Attruby share via payer preference within 12 months.
  • $1.2B debt triggers breaches if Attruby growth drops below 30% YoY.
  • FDA rejects BBP-812 Canavan program halting 40% early pipeline value.

What makes BridgeBio unique

  • Hub-and-spoke model advances 48 disease programs via autonomous subsidiaries.
  • Focuses exclusively on genetic diseases and RAS/PI3Kα-driven cancers.
  • Partners with academics to rescue shelved early-stage genetic research.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Performance Bonus

Company Equity

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 15th, 2026
BridgeBio Pharma shares drop 8% in a month despite 110% yearly gain and analyst target of $100

BridgeBio Pharma has fallen 8% over the past month and 7% over three months, despite posting a 110.52% one-year total shareholder return and approximately 4x returns over three years. The company closed at $69.41, with analysts from Vestra pointing to a fair value of $100.05, suggesting it's 30.6% undervalued. The valuation gap depends on BridgeBio's late-stage pipeline and its transition from research and development to commercial operations. However, the company continues to carry annual net losses of approximately $724.9 million, keeping financing and execution risks prominent. A separate DCF model estimates future cash flow value at $302.08, though this relies heavily on long-term assumptions around successful regulatory approvals and commercial uptake across its rare disease portfolio.

Yahoo Finance
Mar 7th, 2026
BridgeBio's BBP-418 hits Phase 3 endpoints in LGMD2I/R9, but $673M loss tests diversification thesis

BridgeBio Pharma announced positive interim Phase 3 FORTIFY trial data for BBP-418 in limb-girdle muscular dystrophy type 2I/R9, meeting efficacy endpoints. The company will present expanded results at the 2026 MDA Clinical and Scientific Conference alongside additional research. The successful readout represents a significant step for BBP-418 as a potential therapy for the rare genetic muscle disorder and could help diversify BridgeBio's revenue beyond its single approved drug, Attruby. However, the company remains unprofitable, reporting US$502 million in revenue against a US$725 million net loss in 2025. Analysts project BridgeBio could reach US$1.7 billion in revenue by 2028, with a fair value estimate of US$100.05 per share. The key risk remains high cash burn and potential dilution if expenses continue outpacing revenue growth.

Yahoo Finance
Mar 6th, 2026
Truist raises BridgeBio price target to $95 as Attruby sales hit $146M in Q4

BridgeBio Pharma has received upgraded price targets from analysts following strong fourth-quarter results. Truist raised its target to $95 from $86, maintaining a Buy rating, whilst Morgan Stanley increased its target to $98 from $96 with an Overweight rating. The company reported fourth-quarter revenue of $154.18 million, exceeding the $149.07 million consensus estimate. Pre-announced sales of its drug Attruby reached $146 million, a 35% increase from the third quarter, driven by accelerating new patient additions. CEO Neil Kumar highlighted the company's delivery of three successful Phase 3 trial readouts within three months. BridgeBio develops medicines for patients with genetic diseases and anticipates having six approved products as it completes its first decade.

Yahoo Finance
Jan 20th, 2026
Analysts raise BridgeBio price target to $86 after $362M Attruby revenue in 2025

BridgeBio Pharma has received positive analyst coverage following strong 2025 results. Truist raised its price target to $86 from $80 whilst maintaining a Buy rating, noting unchanged fundamental views from 2025. At the J.P. Morgan Healthcare Conference on 12 January, BridgeBio announced preliminary unaudited revenues of $146 million for the fourth quarter of 2025, bringing full-year product revenue to $362.4 million. The company reported over 6,000 unique prescriptions for Attruby, demonstrating rapid market adoption as a first-choice treatment for newly diagnosed ATTR-CM patients. BridgeBio develops therapies for genetic diseases and cancers, including its oncology-focused spin-off, BridgeBio Oncology Therapeutics, which advances precision cancer treatments targeting oncogenes like RAS and PI3K.

Stock Titan
Jan 16th, 2026
BridgeBio prices $550M convertible notes offering to prefund 2027 debt repayment

BridgeBio has priced an offering of $550 million in convertible senior notes due 2033. The biotech company plans to use the proceeds to prefund the repayment of its existing convertible senior notes due 2027. The refinancing move allows BridgeBio to extend its debt maturity profile by six years whilst managing its capital structure ahead of the 2027 notes coming due.

INACTIVE